Market Research Reports on Treating Refractory Hematological Malignancies - 0 views
-
Matilde Fernandes on 14 Jan 14Treating refractory hematological malignancies unfold a host of competition and commercial opportunities. Approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts attract swarming competition. There is severe competition amongst the companies to launch new therapies for this indication. Companies leading in the race to launch such therapies include Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene.